Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels

Abstract

Context.-Although cholesterol-reducing treatment has been shown to reduce fatal and nonfatal coronary disease in patients with coronary heart disease (CHD), it is unknown whether benefit from the reduction of low-density lipoprotein cholesterol (LDL-C) in patients without CHD extends to individuals with average serum cholesterol levels, women, and older persons. Objective.-To compare lovastatin with placebo for prevention of the first acute major coronary event in men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levels. Design.-A randomized, double-blind, placebo-controlled trial. Setting.-Outpatient clinics in Texas. Participants.-A total of 5608 men and 997 women with average TC and LDL-C and below-average HDL-C (as characterized by lipid percentiles for an age-and sex-matched cohort without cardiovascular disease from the National Health and Nutrition Examination Survey [NHANES] III). Mean (SD) TC level was 5.71 (0.54) mmol/L (221 [21] mg/dL) (51st percentile), mean (SD) LDL-C level was 3.89 (0.43) mmol/L (150 [17] mg/dL) (60th percentile), mean (SD) HDL-C level was 0.94 (0.14) mmol/L (36 [5] mg/dL) for men and 1.03 (0.14) mmol/L (40 [5] mg/dL) for women (25th and 16th percentiles, respectively), and median (SD) triglyceride levels were 1.78 (0.86) mmol/L (158 [76] mg/dL) (63rd percentile). Intervention.-Lovastatin (20-40 mg daily) or placebo in addition to a lowsaturated fat, low-cholesterol diet. Main Outcome Measures.-First acute major coronary event defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death. Results.-After an average follow-up of 5.2 years, lovastatin reduced the incidence of first acute major coronary events (183 vs 116 first events;

A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey

“…Dyslipidemia, particularly elevated levels of low-density lipoprotein cholesterol (LDL-C), increases the risk of coronary artery disease (CAD) (3)(4)(5)(6)(7)(8)(9)(10)(11).…”

The association between 3‐hydroxy‐3‐methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women

“…3 One randomized clinical drug trial lasting 5 years reported 12 breast carcinoma cases among pravastatin users and only 1 case in the placebo group (P ϭ 0.002), 4 but this finding was not confirmed in other clinical trials of statin use. [5][6][7] Evidence concerning the carcinogenicity of statins from clinical drug trials and observational studies remains inconclusive because of inconsistent results between studies, the limited range of statin exposure duration, and inadequate sample sizes. 4 -13 Contrary to concerns regarding the carcinogenicity of statins, a growing body of evidence suggests that statins may in fact have a chemopreventive potential against cancer.…”

Prevention challenges: The era of atherosclerosis regression

“…Several large-scale, randomized, placebo-controlled clinical trials have demonstrated that LDL cholesterol lowering with statin therapy reduces morbidity and mortality in patients with or at risk of cardiovascular diseases (7)(8)(9)(10). More recent active comparator statin trials have demonstrated that aggressive lowering of LDL cholesterol provides additional benefits over more moderate lowering.…”